Anal Intraepithelial Neoplasia: A Population Study

  • Research type

    Research Study

  • Full title

    The Role of Early Detection and Treatment of Anal Intraepithelial Neoplasia in the Prevention of Anal Squamous Cell Carcinoma: A Population Study.

  • IRAS ID

    240977

  • Contact name

    Paris Tekkis

  • Contact email

    paris.tekkis@rmh.nhs.uk

  • Sponsor organisation

    Imperial College Healthcare NHS Trust

  • Duration of Study in the UK

    1 years, 7 months, 12 days

  • Research summary

    Anal Interstitial Neoplasia (AIN) is a precursor to Anal Squamous Cell Carcinoma (ASCC). It is a Human Papillomavirus linked cancer and has an incidence of between 1-2 per 100,000 per year. It is also associated with HIV and its incidence is increasing due to the higher prevalence of HIV. We expect ASCC to become an increasing burden on cancer services as advanced antiretroviral therapy allows patients with HIV to live longer.
    The progression of AIN to ASCC is unpredictable and many patients do not progress from the earliest grades of AIN to ASCC in predictable patterns. AIN exists in 3 grades: AIN1 (low risk of progression), AIN2 (moderate risk of progression) and AIN3 (cancer-in-situ). Understanding the risk factors that predict the progression of AIN will lead to the better treatment of patients with AIN3 at the highest risk of developing anal cancer.
    We propose to review our previous ASCC diagnoses as well as patients who have attended AIN screening clinics at Chelsea and Westminster Hospitals NHS Foundation Trust with an aim to amalgamate this data to allow us to assess outcomes of patients being treated with low grade and high-grade AIN and see if we could have prevented the development of ASCC.
    Any patients diagnosed after study HRA approval with Anal SCC will be propectively recruited and consented to take part in the study and have their data included.
    From this information we aim to produce a risk assessment tool that could help us identify patients with AIN 3 at the highest risk of developing anal cancer.

  • REC name

    London - Westminster Research Ethics Committee

  • REC reference

    18/LO/0659

  • Date of REC Opinion

    23 Apr 2018

  • REC opinion

    Favourable Opinion